The 2009 Congress of the European Society of Cataract and Refractive Surgeons and Presbyopia International 2009 Symposium took place against a backdrop of relative optimism within the refractive surgery industry. There are signs that the laser vision correction market may have hit bottom during the middle of 2009.

ImVisioN GMBH's focus is allergy immunotherapy, and it is using its platform technologies to create a pipeline of treatments for major allergies. ILIT, ImVisioN's delivery technology, allows administration of the allergen directly into the lymph nodes, which contain high concentrations of antigen-presenting cells. Its MAT technology is designed to maximize the immune protective response from T helper cell type 1 and minimize the Th2-mediated inflammatory responses.